Kura Oncology (NASDAQ:KURA) Price Target Raised to $40.00

Kura Oncology (NASDAQ:KURA - Free Report) had its price objective lifted by HC Wainwright from $37.00 to $40.00 in a report released on Thursday,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts also recently weighed in on KURA. Wedbush restated an "outperform" rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Monday, November 4th. JMP Securities reissued a "market outperform" rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Tuesday, November 19th. Lifesci Capital upgraded Kura Oncology to a "strong-buy" rating in a research report on Tuesday, October 22nd. Jefferies Financial Group reduced their target price on Kura Oncology from $32.00 to $28.00 and set a "buy" rating on the stock in a report on Thursday, November 21st. Finally, UBS Group assumed coverage on shares of Kura Oncology in a report on Thursday, October 24th. They set a "buy" rating and a $27.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $27.13.

Kura Oncology Trading Up 1.6 %

Shares of KURA stock traded up $0.14 during mid-day trading on Thursday, reaching $8.79. 752,907 shares of the stock traded hands, compared to its average volume of 1,884,173. The company has a market cap of $683.59 million, a price-to-earnings ratio of -3.73 and a beta of 0.78. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock's fifty day simple moving average is $8.74 and its two-hundred day simple moving average is $14.95. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter last year, the company earned ($0.50) EPS. On average, research analysts anticipate that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Activity at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,255 shares of company stock valued at $100,739 in the last three months. Corporate insiders own 5.50% of the company's stock.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently made changes to their positions in the company. Suvretta Capital Management LLC grew its position in Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock worth $149,535,000 after purchasing an additional 583,155 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company's stock valued at $34,798,000 after acquiring an additional 41,535 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Kura Oncology by 1.5% during the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company's stock valued at $28,687,000 after acquiring an additional 23,113 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Kura Oncology by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 635,494 shares of the company's stock worth $5,535,000 after acquiring an additional 10,542 shares during the period. Finally, Alethea Capital Management LLC boosted its position in Kura Oncology by 108.2% in the third quarter. Alethea Capital Management LLC now owns 553,542 shares of the company's stock worth $10,816,000 after purchasing an additional 287,636 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.